In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Self-Protective Partnering

Executive Summary

A self-protective dynamic characterizes a licensing deal that Gilead just signed for its new hepatitis B treatment adefovir, which is expected to win regulatory approval shortly. By assigning to Glaxo product rights in Asia--the largest market for the drug, but beyond still-small Gilead's reach--the biotech firm assures that a big, strong competitor can't play too rough with it. Glaxo's tacit endorsement of the drug's quality should help Gilead's efforts to market the product in the US and Europe, where it kept rights.
Advertisement

Related Content

Gilead's Global Logic
Gilead's Global Logic

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV001905

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel